$10.68
0.56% today
Nasdaq, Feb 05, 04:13 pm CET
ISIN
US15870P3073
Symbol
CSBR
Sector
Industry

Champions Oncology, Inc. Stock price

$10.74
+1.27 13.41% 1M
+5.94 123.75% 6M
+2.17 25.32% YTD
+4.67 76.94% 1Y
+2.92 37.36% 3Y
+2.99 38.58% 5Y
+5.94 123.75% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
+0.73 7.29%
ISIN
US15870P3073
Symbol
CSBR
Sector
Industry

Key metrics

Market capitalization $148.42m
Enterprise Value $152.74m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.85
P/S ratio (TTM) P/S ratio 2.77
P/B ratio (TTM) P/B ratio 216.05
Revenue growth (TTM) Revenue growth 7.19%
Revenue (TTM) Revenue $53.57m
EBIT (operating result TTM) EBIT $-352.00k
Free Cash Flow (TTM) Free Cash Flow $-2.82m
Cash position $2.75m
EPS (TTM) EPS $-0.05
P/S forward 2.65
EV/Sales forward 2.72
Short interest 3.96%
Show more

Is Champions Oncology, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Champions Oncology, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Champions Oncology, Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Champions Oncology, Inc.:

Buy
100%

Financial data from Champions Oncology, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Oct '24
+/-
%
54 54
7% 7%
100%
- Direct Costs 30 30
1% 1%
55%
24 24
16% 16%
45%
- Selling and Administrative Expenses 15 15
4% 4%
28%
- Research and Development Expense 7.38 7.38
35% 35%
14%
1.72 1.72
128% 128%
3%
- Depreciation and Amortization 2.08 2.08
17% 17%
4%
EBIT (Operating Income) EBIT -0.35 -0.35
96% 96%
-1%
Net Profit -0.60 -0.60
94% 94%
-1%

In millions USD.

Don't miss a Thing! We will send you all news about Champions Oncology, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Champions Oncology, Inc. Stock News

Neutral
Accesswire
28 days ago
HACKENSACK, NJ / ACCESSWIRE / January 8, 2025 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading technology-enabled oncology research organization with specialty testing services, is excited to announce significant advancements in its bioanalytical services portfolio, specifically, expanding its capabilities with the integration of multiple global Cytek Aurora flow cytometers and the appointme...
Neutral
Seeking Alpha
about one month ago
Champoins Oncology broke out of a multiyear downtrend following its Q2'25 earnings. Management has embarked on a one-way journey to reduce working capital and grow the business with zero incremental capital. This has succeeded and the business is now in a prime position to grow sales at 10% CAGR to CY'26 in my opinion.
More Champions Oncology, Inc. News

Company Profile

Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.

Head office United States
CEO Ronnie Morris
Employees 210
Founded 1985
Website www.championsoncology.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today